Description of the study population according to treatment group
 |
| |||
Description of the study population according to treatment group
| Adefovir (n = 29) | Tenofovir (n = 56) | p | |
|---|---|---|---|
| Demographics | |||
| Sex Male/Female (% Males) | 28/1 (96.6) | 54/2 (96.4) | ns |
| Age, years (median, SD) | 41.5 (7.7) | 42.3 (7.2) | ns |
| Country of origin HBV prevalence > 2% (n, %) | 5 (17.2) | 9 (16.1) | ns |
| Characteristics of HIV infection | |||
| Duration of HIV Infection, years (mean, SD) | 10.7 (5.3) | 10.7 (4.5) | ns |
| History of an AIDS-defining event (n, %) | 5 (17.2) | 9 (16.1) | ns |
| Nb (%) of patients treated with ARV before inclusion patients | 26 (89.7) | 53 (94.6) | ns |
| Other ARV treatments associated at baseline | ns | ||
| 2 NRTI (n, %) | 2 (6.9) | 4 (7.1) | |
| 1 NRTI + 1 NNRTI (n, %) | 3 (10.3) | 6 (10.7) | |
| 1 NRTI + 1 PI (n, %) | 13 (44.8) | 18 (32.1) | |
| 1 NRTI + 1 NNRTI + 1 PI (n, %) | 9 (31.0) | 28 (50.0) | |
| CD4 T cell count, per mm3 (mean, SD) | 482 (298) | 457 (250) | ns |
| Rate of HIV-RNA above detection limit (n, %) | 14 (53.9) | 29 (51.8) | ns |
| HIV-RNA, log10 copies/mL (median, IQR) | 1.88 (1.70–3.81) | 1.84 (1.70–4.14) | ns |
| Characteristics of HBV infection | |||
| Duration of HBV Infection years (mean, SD) | 8.3 (4.6) | 7.7 (5.0) | ns |
| Presence of serum HBe Ag (n, %) | 25 (86.2) | 50 (89.3) | ns |
| Presence of serum antiHBe Ab (n, %) | 4 (15.4) | 6 (10.9) | ns |
| HBV-DNA, log10 copies/mL (median, IQR) | 8.30 (6.56 – 9.10) | 7.30 (6.00 – 8.30) | ns |
| HCV co-infection (n, %) | 3 (10.3) | 4 (7.1) | ns |
| HDV co-infection (n, %) | 2 (6.9) | 2 (3.6) | ns |
| History of treatment with lamivudine (n, %) | 26 (89.7) | 50 (89.3) | ns |
| Duration of treatment with lamivudine, months(mean, SD) | 69.6 (27.8) | 63.8 (28.1) | ns |
| Co-treatment with lamivudine during study (n, %) | 19 (65.5) | 44 (78.6) | ns |
| History of treatment with Interferon or PegInterferon (n, %) | 5 (17.3) | 4 (7.1) | ns |
| Fibrosis METAVIR score F0–F1 v. F2 v. F3–F4 (n, %) | 2 (8.7) – 8 (34.8) – 13 (56.5) | 14 (38.9) – 10 (27.8) – 12 (33.3) | 0.02 |
| Activity METAVIR score A0–A1 v. A2 v. A3 (n, %) | 22 (52.2) – 9 (39.1) – 2 (8.7) | 22 (61.1) – 11 (30.6) – 3 (8.3) | ns |
| YMDD mutants, n=75 (n, %) | 21 (91.3) | 39 (75.0) | ns |
| Pre Core mutants (W28 mutation), n=65 (n, %) | 3 (30.0) | 9 (16.4) | ns |
| ALT IU/mL (mean, SD) | 134 (150) | 90 (93) | ns |